

Lung Cancer: Non-Small Cell Pathways

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

ICD-10 Code: _____ Pathology: _____

Stage: __IA__IB__IIA__IIB__IIIA__IIIB__IV__ Recurrent

Line of Treatment: __ Neoadjuvant/Pre-Op __ Adjuvant/Post-Op __ First Line __ Second Line __ Third Line __ Third Line+ __ Maintenance

ECOG Performance Status: __ 0 __ 1 __ 2 __ 3 __ 4

Biomarker:

ALK status: __ Positive __ Negative __ Not reported

EGFR: __ Mutation __ Wild type __ Not reported

BRAF: __ V600E Mutation __ V600K Mutation __ Wild type __ Not reported

MET amplification: __ Positive __ Negative __ Not reported

RET gene rearrangement: __ Absent __ Present __ Not reported

ROS1 rearrangement: __ Positive __ Negative __ Not reported

Adjuvant Therapy

Cisplatin (Platinol) and vinorelbine (Navelbine)

Gemcitabine (Gemzar) and cisplatin (Platinol)

Paclitaxel (Taxol) and carboplatin (Paraplatin)

Primary Therapy for Locally Advanced/Unresectable | Stage III

Paclitaxel (Taxol) (Q3Wks) and carboplatin (Paraplatin) with XRT

Metastatic disease | ALK+ | First line (1st line)

Alectinib (Alecensa)

Metastatic disease | EGFR+ | First line (1st line)

Afatinib (Gilotrif)

Erlotinib (Tarceva)

Metastatic disease | Non-squamous | ECOG PS: 0, 1, 2 | First line (1st line)

Carboplatin† (Paraplatin) and paclitaxel (Taxol)

Cisplatin† (Platinol) and gemcitabine (Gemzar)

Cisplatin† (Platinol) and pemetrexed (Alimta)

Paclitaxel (Taxol) and carboplatin (Paraplatin) and bevacizumab (Avastin)

* Administered at a dose of 2 mg/kg (up to a maximum of 200 mg).

† In the setting of recurrent/metastatic NSCLC, a substitution of carboplatin for cisplatin (or vice-versa) will be considered a Pathway option



Lung Cancer: Non-small Cell Pathways

(continued)

Metastatic disease | Squamous | ECOG PS: 0, 1, 2 | First line (1st line)

__ Carboplatin† (Paraplatin) and paclitaxel (Taxol)

__ Cisplatin† (Platinol) and gemcitabine (Gemzar)

Metastatic disease | PD-L1 Positive | First Line (1st line)

__ Pembrolizumab* (Keytruda)

Metastatic disease | Non-squamous | ECOG PS: 0, 1, 2 | Maintenance

__ Continuation bevacizumab (Avastin)

__ Continuation pemetrexed (Alimta)

__ Switch pemetrexed (Alimta)

Metastatic disease | ALK+ or EGFR+ | ECOG PS: 0, 1, 2 | Second line (2nd line) after targeted 1st line therapy

__ Carboplatin† (Paraplatin) and paclitaxel (Taxol)

__ Cisplatin† (Platinol) and gemcitabine (Gemzar)

__ Cisplatin† (Platinol) and pemetrexed (Alimta)

Metastatic disease | EGFR T790M mutation | Second line (2nd line) after targeted 1st line therapy

__ Osimertinib (Tagrisso)

Metastatic disease | Non-squamous | ECOG PS: 0, 1, 2 | Second line (2nd line)

__ Docetaxel (Taxotere)

__ Nivolumab (Opdivo)

__ Pemetrexed (Alimta)

Metastatic disease | Squamous | ECOG PS: 0, 1, 2 | Second line (2nd line)

__ Nivolumab (Opdivo)

* Administered at a dose of 2 mg/kg (up to a maximum of 200 mg).

† In the setting of recurrent/metastatic NSCLC, a substitution of carboplatin for cisplatin (or vice-versa) will be considered a Pathway option